TrialInternational journal of clinical oncology2020

A phase II trial of dose-reduced nab-paclitaxel for patients with previously treated, advanced or recurrent gastric cancer (OGSG 1302).

Shigeyuki Tamura et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.